« Back to Record
Almhanna, K., Bendell, J., Bols, A., Feliu, J., Starling, N., Enzinger, P., Mahalingham, D., Messersmith, W., Yang, H., Fasanmade, A. A., Danaee, H., Wright, D., Kalebic, T., Mercade, T. M., Van Laethem, J.-L., Gracian, A. C., Guillen-Ponce, C., Faris, J., López, C. M., & Hubner, R. R. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational new drugs, 35(5), 634-641. doi:10.1007/s10637-017-0473-9
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/260744



